Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's ...

In a study known as CROWNS-2 published in JAMA, the researchers randomly assigned 180 adults with CRSwNP to stapokibart (300 ...

Shares of GSK PLC GSK inched up 0.98% to £14.39 Monday, on what proved to be an all-around positive trading session for the ...

Bristol Myers leans on new launches to offset legacy drug declines, while GSK's diverse portfolio and strong HIV lineup keep growth on track.

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

Dynavax Technologies has revealed promising topline outcomes from the initial part of its Phase I/II clinical trial, ...

The Emeryville, California-based biotech has just released topline results from a phase 1/2 head-to-head study comparing its ...

As an award-winning actress in films like What’s Love Got to Do With It, Malcolm X, Waiting to Exhale and Black Panther, ...

Wes Streeting has walked away from talks with pharmaceutical giants on NHS drug costs amid a stand-off over rebates. The ...

With three new antibiotics set to shake up the stagnant treatment landscape for uncomplicated urinary tract infections (uUTIs ...

Dynavax (DVAX) stock gains as the company's Z-1018 shingles shot shows immune response comparable to GSK's (GSK) Shingrix vaccine in a Phase 1/2 trial. Read more here.

The leading Chronic Refractory Cough Companies such as GSK, Trevi Therapeutics, Patara Pharma, Vyne Therapeutics Inc., Nerre ...